Cargando…
Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
Disabling hearing loss impacts ∼466 million individuals worldwide with 34 million children affected. Gene and pharmacotherapeutic strategies to rescue auditory function in mouse models of human deafness are most effective when administered before hearing onset, after which therapeutic efficacy is si...
Autores principales: | Wang, Lingyan, Kempton, J Beth, Jiang, Han, Jodelka, Francine M, Brigande, Alev M, Dumont, Rachel A, Rigo, Frank, Lentz, Jennifer J, Hastings, Michelle L, Brigande, John V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229850/ https://www.ncbi.nlm.nih.gov/pubmed/32249312 http://dx.doi.org/10.1093/nar/gkaa194 |
Ejemplares similares
-
Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells
por: Michaels, Wren E, et al.
Publicado: (2020) -
iRAPs curb antisense transcription in E. coli
por: Magán, Andrés, et al.
Publicado: (2019) -
Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse
por: Depreux, Frederic F., et al.
Publicado: (2016) -
Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs
por: Pfafenrot, Christina, et al.
Publicado: (2021) -
Global RNA profiles show target selectivity and physiological effects of peptide-delivered antisense antibiotics
por: Popella, Linda, et al.
Publicado: (2021)